Plain-English translation of NCT03971045 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination treatment for a difficult-to-treat type of breast cancer that has spread to the chest wall. The combination includes , an immunotherapy drug that helps your immune system fight cancer, plus a low-dose oral chemotherapy pill called cyclophosphamide taken daily. Researchers want to see if giving these two drugs together is safe and effective for patients who have already received other cancer treatments.
Breast cancer that has spread to the chest wall is hard to treat with surgery alone, and many patients need new options. This medication works differently than traditional chemotherapy by helping the body's own immune system recognize and attack cancer cells, which is why researchers are studying whether combining it with low-dose daily chemotherapy might be more effective.
You likely qualify if…
You likely don't qualify if…
You would receive as an intravenous infusion (through an IV) every 21 days at the study center, and take cyclophosphamide as an oral pill (50 mg) every day at home. The study continues for up to 24 months unless your cancer progresses, you experience unacceptable side effects, or you decide to stop. You will have regular check-ups, blood tests, imaging scans, and biopsies to monitor how the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Italy